Related Experiment Video
Updated: May 23, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top
Theresa L Whiteside1, Soldano Ferrone
1Department of Pathology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA. whitesidetl@upmc.edu
Abstract:
The stromal immunoglobulin kappa chain (IGKC) has been validated as an immunologic biomarker of prognosis and response to therapy in human breast cancer and other cancers. This validation emphasizes the key role of humoral immunity in control of cancer progression and has major implications for determining prognosis of patients with cancer.
Related Concept Videos
Mitogens and the Cell Cycle
Tumor Immunotherapy
Cancer Survival Analysis
